“I had treatment last year and I want to give something back.”
A trial looking at trastuzumab (Herceptin) with chemotherapy for early breast cancer (SOLD)
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial compared trastuzumab (Herceptin) and chemotherapy, to Herceptin and chemotherapy followed by more Herceptin. It was for women with early breast cancer that was HER2 positive. This trial was supported by Cancer Research UK.
More about this trial
- docetaxel chemotherapy and Herceptin at the same time to start with, then
- a combination of chemotherapy called FEC (fluorouracil, epirubicin and cyclophosphamide)
Summary of results
- half didn’t have any more Herceptin
- half had Herceptin for about another 10 months (so about a year in total)
- 88% of those who’d had Herceptin for 9 weeks
- 91% of those who’d had Herceptin for a year
- 73 women (7%) who’d had Herceptin for 9 weeks
- 61 women (6%) who’d had Herceptin for a year
- 34 women (3%) who’d had Herceptin for 9 weeks
- 33 women (3%) who’d had Herceptin for a year
- 22 women (2%) who had Herceptin for 9 weeks
- 42 women (4%) who had Herceptin for a year
- 63% for women who had Herceptin for 9 weeks
- 61% for women who had Herceptin for a year
How to join a clinical trial
Dr Judy fraser
This is Cancer Research UK trial number CRUKE/10/033.